• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估 miR-8073 和 miR-642 作为胰腺癌诊断标志物的潜力。

Evaluation of potential of miR-8073 and miR-642 as diagnostic markers in pancreatic cancer.

机构信息

Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Mol Biol Rep. 2022 Jul;49(7):6475-6481. doi: 10.1007/s11033-022-07476-0. Epub 2022 May 20.

DOI:10.1007/s11033-022-07476-0
PMID:35596051
Abstract

BACKGROUND

Pancreatic cancer is a cancer with an insidious course. Since disease is often diagnosed at advanced stages, clinical outcome is impaired. Thus identification of biomarkers for this malignancy has importance in enhancement of patients' survival.

METHODS AND RESULTS

In the current study, we assessed expression levels of miR-8073 and miR-642 in the circulation of 50 patients with pancreatic cancer and 50 controls. Plasma levels of miR-8073 and miR-642 were significantly higher in patients with pancreatic cancer compared with controls (P value < 0.0001 and P value = 0.0068, respectively). Plasma levels of miR-642 were inversely correlated with albumin levels (R=-0.28, P value = 0.049), WBC count (R=-0.35, P value = 0.01), as well as CRP level (R=-0.30, P value = 0.035). On the other hand, levels of this miRNA were positively correlated with lipase level (R = 0.29, P value = 0.042). Levels of miR-8073 were not correlated with any of the available parameters. Plasma levels of miR-8073 could separate patients with pancreatic cancer from controls with AUC, sensitivity and specificity values of 0.82, 0.77 and 0.78, respectively. miR-642 could differentiate these two groups with AUC, sensitivity and specificity values of 0.63, 0.58 and 0.78, respectively. Combination of these two parameters resulted in AUC, sensitivity and specificity values of 0.79, 0.77 and 0.78, respectively.

CONCLUSIONS

Taken together, these two miRNAs are suggested as possible blood markers for pancreatic cancer.

摘要

背景

胰腺癌是一种隐匿性很强的癌症。由于疾病通常在晚期才被诊断出来,因此临床预后受到影响。因此,鉴定这种恶性肿瘤的生物标志物对于提高患者的生存率具有重要意义。

方法和结果

在本研究中,我们评估了 50 名胰腺癌患者和 50 名对照者循环中 miR-8073 和 miR-642 的表达水平。与对照组相比,胰腺癌患者的血浆 miR-8073 和 miR-642 水平显著升高(P 值均<0.0001 和 P 值=0.0068)。miR-642 的血浆水平与白蛋白水平(R=-0.28,P 值=0.049)、白细胞计数(R=-0.35,P 值=0.01)以及 CRP 水平(R=-0.30,P 值=0.035)呈负相关。另一方面,miRNA 的水平与脂肪酶水平呈正相关(R=0.29,P 值=0.042)。miR-8073 的水平与所有可用参数均无相关性。miR-8073 的血浆水平能够以 AUC、敏感性和特异性值为 0.82、0.77 和 0.78 将胰腺癌患者与对照组区分开来。miR-642 能够以 AUC、敏感性和特异性值为 0.63、0.58 和 0.78 将这两组区分开来。将这两个参数结合起来,得到的 AUC、敏感性和特异性值分别为 0.79、0.77 和 0.78。

结论

综上所述,这两种 miRNA 可作为胰腺癌的潜在血液标志物。

相似文献

1
Evaluation of potential of miR-8073 and miR-642 as diagnostic markers in pancreatic cancer.评估 miR-8073 和 miR-642 作为胰腺癌诊断标志物的潜力。
Mol Biol Rep. 2022 Jul;49(7):6475-6481. doi: 10.1007/s11033-022-07476-0. Epub 2022 May 20.
2
Integrating MicroRNA Expression Profiling Studies to Systematically Evaluate the Diagnostic Value of MicroRNAs in Pancreatic Cancer and Validate Their Prognostic Significance with the Cancer Genome Atlas Data.整合微小RNA表达谱研究以系统评估微小RNA在胰腺癌中的诊断价值,并利用癌症基因组图谱数据验证其预后意义。
Cell Physiol Biochem. 2018;49(2):678-695. doi: 10.1159/000493033. Epub 2018 Aug 30.
3
MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers.用于诊断胰腺癌和胆管癌的微小RNA标志物。
PLoS One. 2015 Feb 23;10(2):e0118220. doi: 10.1371/journal.pone.0118220. eCollection 2015.
4
Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation.循环 miRNA-21-5p 作为胰腺癌的诊断生物标志物:来自综合 miRNA 表达谱分析和临床验证的证据。
Sci Rep. 2017 May 10;7(1):1692. doi: 10.1038/s41598-017-01904-z.
5
Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis.血浆 miRNAs 在胰腺癌的诊断和预后中的作用:一项 miRNA 表达分析。
Gene. 2018 Oct 5;673:181-193. doi: 10.1016/j.gene.2018.06.037. Epub 2018 Jun 18.
6
MicroRNA biomarkers in whole blood for detection of pancreatic cancer.全血中的 microRNA 标志物用于胰腺癌检测。
JAMA. 2014;311(4):392-404. doi: 10.1001/jama.2013.284664.
7
MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease.胰腺癌患者血浆中的微小RNA作为新型疾病血液生物标志物
Cancer Prev Res (Phila). 2009 Sep;2(9):807-13. doi: 10.1158/1940-6207.CAPR-09-0094. Epub 2009 Sep 1.
8
Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis.鉴定血清中六miRNA 标志物panel 有益于胰腺癌诊断。
Cancer Med. 2019 Jun;8(6):2810-2822. doi: 10.1002/cam4.2145. Epub 2019 Apr 21.
9
MicroRNA-196b is an independent prognostic biomarker in patients with pancreatic cancer.微小RNA-196b是胰腺癌患者的独立预后生物标志物。
Carcinogenesis. 2017 Apr 1;38(4):425-431. doi: 10.1093/carcin/bgx013.
10
Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value.基于微小RNA表达谱的胰腺癌分子亚型具有独立的预后价值。
J Gastroenterol Hepatol. 2016 Jun;31(6):1160-7. doi: 10.1111/jgh.13253.

引用本文的文献

1
Clinical Value of Circulating miRNA in Diagnosis, Prognosis, Screening and Monitoring Therapy of Pancreatic Ductal Adenocarcinoma-A Review of the Literature.循环 miRNA 在胰腺导管腺癌的诊断、预后、筛查和监测治疗中的临床价值——文献综述。
Int J Mol Sci. 2023 Mar 7;24(6):5113. doi: 10.3390/ijms24065113.

本文引用的文献

1
miR-642 serves as a tumor suppressor in hepatocellular carcinoma by regulating SEMA4C and p38 MAPK signaling pathway.微小RNA-642通过调节SEMA4C和p38丝裂原活化蛋白激酶信号通路在肝细胞癌中发挥肿瘤抑制作用。
Oncol Lett. 2020 Oct;20(4):74. doi: 10.3892/ol.2020.11935. Epub 2020 Jul 30.
2
The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.CA19-9 在胰腺腺癌中的临床应用:诊断和预后更新。
Curr Mol Med. 2013 Mar;13(3):340-51. doi: 10.2174/1566524011313030003.